Nature Medicine, Published online: 29 April 2026; doi:10.1038/s41591-026-04366-x
Preclinical and phase 1/2 trial data show that anti-CD38 monoclonal antibody treatment restores platelet counts in patients with immune thrombocytopenia by increasing nicotinamide adenine dinucleotide (NAD+) levels, and low-dose oral treatment with the NAD+ precursor nicotinamide mononucleotide can similarly increase platelet counts without serious adverse effects.
